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TonBBacteriocins are a diverse group of ribosomally synthesized protein antibiotics produced by most bacteria. They
range from small lanthipeptides produced by lactic acid bacteria to much larger multi domain proteins of Gram
negative bacteria such as the colicins from Escherichia coli. For activity bacteriocins must be released from the
producing cell and then bind to the surface of a sensitive cell to instigate the import process leading to cell
death. For over 50 years, colicins have provided a working platform for elucidating the structure/function
studies of bacteriocin import and modes of action. An understanding of the processes that contribute to the
delivery of a colicin molecule across two lipid membranes of the cell envelope has advanced our knowledge
of protein–protein interactions (PPI), protein–lipid interactions and the role of order–disorder transitions of
protein domains pertinent to protein transport. In this review, we provide an overview of the arrangement of
genes that controls the synthesis and release of themature protein. We examine the uptake processes of colicins
from initial binding and sequestration of binding partners to crossing of the outer membrane, and then discuss
the translocation of colicins through the cell periplasm and across the inner membrane to their cytotoxic site
of action. This article is part of a Special Issue entitled: Protein trafﬁcking and secretion in bacteria. Guest Editors:
Anastassios Economou and Ross Dalbey.
© 2014 Published by Elsevier B.V.1. Introduction
Within the ecological niche of highly diverse communities, there is
often ﬁerce competition between variousmicro-organisms such as bac-
teria, fungi and Archaea for resources and space. Many species have
evolved to produce a huge diversity of antimicrobial molecules that
can either inhibit (bacteriostatic) or kill (bacteriocidal) competitor spe-
cies including broad-spectrum antibiotics, proteinaceous exotoxins, ly-
sozymes, and bacteriocins [1]. Since the discovery of the ﬁrst
bacteriocin by André Gratia nearly 90 years ago from Escherichia coli
[2], bacteriocins have been found in nearly all bacterial lineages and
some Archaea and are now regarded as the most diverse and naturally
abundant classes of antimicrobial molecules [1,3,4]. Gratia's bacteriocin
was termed a ‘colicin’ after the species name of the producing organism.
A similar system of nomenclature was adopted for most bacteriocins
discovered thereafter such as pyocins from Pseudomonas aeruginosa
(formerly Pseudomonas pyocyanea), klebicin from Klebsiellaain, Cytotoxic domain; Col, coli-
ed translocation domain; OM,
F, proton motive force; R do-
on domain
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Penfold).pneumoniae, diffocins from Clostridium difﬁcile, epidermin and
gallidermin from Staphylococcus epidermidis and S. gallinarum respec-
tively, and the newly discovered thuricin 17 from Bacillus thuringiensis.
Despite huge differences in chemical structures and post-translational
processing of bacteriocins between the small (un)modiﬁed
lanthipeptides produced by lactic acid bacteria and the much larger
multi domain polypeptides produced by Gram negative bacteria such
as the colicins, all bacteriocins are ribosomally synthesized proteina-
ceous toxins that share a common biosynthetic pathway. Bacteriocins
are generally narrow spectrum antibacterial agents with biological ac-
tivity against closely related species and their genes are localized on
transposable elements, plasmids or on the chromosome of the
producer's genome. Modes of action range from depolarization of the
lipid bilayer membranes [5,6], disruption of cell wall synthesis [7,8], in-
hibition of protein synthesis or degradation of host nucleic acids [9].
Mechanisms of cellular import are dependent on the target organism;
enzymatic colicins that cross two lipid bilayer membranes and the pep-
tidoglycan layer of the periplasmic space have a very different naviga-
tion pathway than lantibiotics such as mersacidin, which disrupt cell
wall synthesis due to interactions with lipid II on the outside of the
cell wall. The scope of this review is to investigate aspects of bacteriocin
import. In particular, focus will be on the import processes adopted by
colicins (especially enzymatic colicins), which have recently shown
some exciting and novel mechanisms associated with cellular uptake
[10–13].
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2.1. Domain organization and role in uptake
Colicins aremodular proteinswith three functional domains that act
collectively to bind to the outside of a sensitive cell, cross the OM and
translocate to a cytotoxic site of action (Fig. 1). Approximately 30–50%
of the polypeptide is made up of a central receptor binding domain
which interacts with a β-barrel shaped protein in the OM that is normal-
ly involvedwith the import of nutrients andmetal ions such as vitamins,
sugars and Fe3+. An N-terminal translocation domain crosses the OM, in
most cases through interactions with a second outer membrane protein
that acts as a translocator and helps to establish a translocon through in-
teractions with proteins termed Tol (mutations in which render the cell
tolerant of the colicin) or Ton in the host periplasm. The translocator
provides access for the colicin T domain to an energized translocation
system in the periplasm. The T domain is divided into two parts; an
intrinsically unstructured T domain (IUTD) and a larger structured T do-
main (STD) that is distal to the IUTD (Fig. 1). The ﬁnal destination of the
colicin molecule reﬂects the mode of action of the colicin which is either
degradation of host nucleases in the cytoplasm (enzymatic colicins),
depolarization of the cytoplasmic membrane (pore-forming colicins) or
inhibition of peptidoglycan synthesis in the periplasm (colicin M) [14].
Based on this information, colicins are classiﬁed according to (i) the
outer membrane receptor to which they bind and (ii) by themechanism
of translocation through the host periplasm according to Table 1. Import
of Group A colicins occurs through the Tol-dependent translocation sys-
temwhich consists of the proteins TolA, TolB, TolQ, TolR and the peptido-
glycan associated lipoprotein (Pal) whereas import of Group B colicins
occurs through the TonB-dependent translocation system consisting ofFig. 1.Model of the colicin importmechanism. A. Enzymatic colicins such as colicin E3 bind to the
45° from the cell surface. This permits the passage of the IUTD (green dots) through the lumen o
energized by TolA, immunity is released from the colicin-immunity complex and the nuclease d
pendent processingof the colicin at the IM cleaves thenuclease domain from thecolicin in the cyt
B. Colicin Ia uses two copies of the outer membrane receptor, Cir; one for receptor binding and t
dots) followingdistortion of theCir plug (blackdots) to contact TonB at the boundary betweenOM
the pore-forming domain into the IM (orange dashes).proteins TonB, ExbB and ExbD. Translocons of Tol-dependent colicins
generally consist of interactions of the colicin with BtuB, OmpF and the
Tol–Pal system, whereas translocons of the Ton-dependent system
involve interactions of colicin with Ton and either FepA, FhuA or Cir.
The primary receptor Tsx transcends the boundaries between Tol and
Ton as it acts as primary receptor for the Tol-dependent colicin K and
the Ton-dependent colicins 5 and 10 (Table 1). Interestingly, uptake of
vitamin B12 which is TonB-dependent occurs from an initial interaction
at the cell surface with BtuBwhereas the BtuB-mediated uptake of coli-
cins is exclusively associated with the Tol-dependent translocation of
group A colicins rather than TonB (Table 1) [15].2.2. Genetic arrangement of ORFs
Colicins are encoded on colicinogenic plasmids which are either low
molecularweight,multi-copy plasmids of approximately 6 kb containing
few other genetic determinants or high molecular weight, single copy
plasmids in excess of 40 kb that carry many additional genes and are
self-transmissible by conjugation [16]. The genetic organization of coli-
cins varies depending on the type of colicin. The operon of enzymatic co-
licins consists of three genes; the ﬁrst open reading frame in the operon
speciﬁes the structural gene of the colicin (named cxa for colicin x activ-
ity). cxa is immediately followed by a gene for immunity (cxi, named co-
licin x immunity) which constitutively expresses a smaller polypeptide
from its own promoter within cxa to neutralise the cytotoxic nuclease
domain and prevent cell killing of the producing cell on synthesis of
cxa. The third gene in the operon is termed cxl (named colicin x lysis),
which is located distal to cxi and encodes a lysis protein that is involved
in the extracellular release of colicins through lysis of the producer cell.outermembrane receptor, BtuB via their central receptor binding (R) domain at an angle of
f an ompFmonomer and across the OM to capture TolB. The resultant colicin translocon is
omain crosses the cell envelope (orange dots) by an as yet unknown mechanism. FtsH de-
oplasm. In the absence of colicin, TolB forms an interactionwith Pal at themembrane surface.
he 2nd one as a translocator. The ColIa IUTD penetrates the cavity of the translocator (blue
andperiplasm. Energy generated by the TonB–ExbB–ExbD complex promotes transport of
Table 1
Colicin characteristics pertinent to cellular import. Colicins are grouped into two groups, A and B based on the mechanism of translocation across the periplasm.
Colicin Outer membrane receptor “primary receptor” “Translocator” or “secondary receptor” Mechanism of translocation Cytoxicity
Group A
A BtuB OmpF Tol A,B,Q,R Pore-forming
E2, E7, E8, E9 BtuB Omp F Tol A,B,Q,R DNase
E3, E4, E6 BtuB OmpF Tol A,B,Q,R rRNase
E5 BtuB OmpF Tol A,B,Q,R tRNase
E1 BtuB TolC Tol A,R Pore-forming
N LPS OmpF Tol A,Q,R Pore-forming
K Tsx OmpF Tol A,B,Q,R Pore-forming
S4 OmpW Omp F Tol A,B,Q,R Pore-forming
U Omp A Omp F, LPS Tol A,B,Q,R Pore-forming
28b Omp A Omp F, LPS Tol A,B,Q,R Pore-forming
Cloacin DF13 IutA Unknown Tol A,Q,R RNase
Group B
5, 10 Tsx TolC TonB, Exb B,D Pore-forming
Ia, Ib Cir Cir TonB, Exb B,D Pore-forming
B FepA Unknown TonB, Exb B,D Pore-forming
D Fep A Unknown TonB, Exb B,D tRNase
M Fhu A Unknown TonB, Exb B,D Peptidoglycan synthesis inhibitor
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located in the intergenic gap between the colicin and lysis genes and is
constitutively transcribed from the opposite DNA strand from its own
promoter ensuring a constant supply of immunity protein for complete
protection against the colicin [17–19]. Redundancies in the structure
and organization of colicin operons occurs in E group colicins which
often contain additional immunity genes to another nuclease colicin
from a different incompatibility group; for example, the colicin E9 oper-
on on the ColE9-J plasmid contains immunity genes to both ColE9
(DNase) and ColE5 (RNase; [20]). In addition, the ColE9 operon contains
two lysis genes, a complete ColE5 lysis gene and a ColE9 lysis gene that
is truncated and resembles a pseudogene [21]whereas no lysis gene has
been described for the TonB dependent colicins, ColB and ColM [22].
2.3. Extracellular release
Colicins are released by Escherichia coli to kill neighbouring strains of
E. coli and sometimes other enterobacteriacaea such as Citrobacter and
Shigella [23,24]. Colicin expression is tightly regulated by the LexA and
RecA proteins of the SOS response [19,25]. LexA binds to the SOS pro-
moter and represses colicin gene expression which is reversed by the
RecA dependent inactivation of LexA following a period of DNA damage.
As colicin release kills the producing cell (reviewed below), colicin pro-
duction is further regulated by IscR, a global transcriptional regulator
that co-operatively stabilizes LexA at the SOS promoter and temporarily
prevents the RecA-mediated inactivation of LexA ensuring colicins are
only produced in response to persistent DNA damage and after all
DNA repair mechanisms have been exhausted [26]. Populations of coli-
cin producing E. coli produce colicin by autoinduction [27–29] when the
cell enters the stationary growth phase, presumably as an offensive
strategy to move into unoccupied environments offering more
favourable conditions when nutrients become depleted and the cell en-
ters a period of environmental stress [30,31]. The majority of studies on
colicin release were conducted over twenty years ago on group A coli-
cins; colicins A and N, E type colicins such as colicin E2 and E3, and
cloacin DF13, a colicin orthologue produced by Enterobacter cloacae
which all contain a lysis gene downstream of immunity on the colicin
operon [32–37]. Colicins do not possess their own N-terminal signal se-
quence [38] and colicin release is independent of any inner membrane
secretion pathway or deﬁned excretion pathway [37]. Release of coli-
cins, along with other intracellular proteins such as Elongation Factor-
Tu and alkalinephosphatase, occurs by leakage through a permeabilized
OM following lysis or quasi-lysis (dependent on the level of colicininduction) after expression of the lysis gene, which encodes a protein
called the bacteriocin release protein (BRP), lysis or Kil protein from
the same SOS promoter that regulates colicin production [34]. This en-
sures timely release of colicin following concomitant synthesis of both
colicin and BRP, and controlled repression of BRP synthesis in the ab-
sence of colicin expression as the BRP protein can cause host cell lysis
in the absence of colicin production [38,39]. The BRP is a lipoprotein
with a stable signal sequence that is synthesized as a precursor and con-
tains a conserved sequence of residues, Leu-X-Y-Cys, called the lipobox,
around the cleavage site andwhere X and Y are neutral amino acids [40,
41]. The signal sequence inserts into the IM and maturation of the lysis
protein occurs following proteolytic cleavage of the signal sequence and
modiﬁcation of the BRP by acylation of the Cys residue [40]. Insertion of
the mature BRP into the IM causes localized disruption and movement
of the colicin across the IM [42] by an unknown process that requires
co-operative behaviour between the BRP and the cleaved BRP signal se-
quence [42–44]. Mutations to key residues in the lipobox of the BRP
prevented any accumulation of the colicin in the periplasm presumably
by disruption to the transport processes of colicin across the IM
resulting from a näive BRP [42,45]. The BRP of colicins and cloacin
DF13 traverse the IM and associate with the OM [44]. Disruption of
the local symmetry of the OM activates phospholipase A resulting in in-
creased permeability of the lipid bilayer most probably through phos-
pholipase A mediated changes to the lipid composition of the bilayer
[47]. The role of phospholipase A in colicin export has been supported
by the observation that pldAmutants defective in lipase activity do not
appear to release colicin following induction of the colicin operon [37].
However, BRP-mediated perturbations of the OM are enough to cause
colicin release, albeit at a reduced rate, in the absence of any phospholi-
pase activity [47].
Colicins do not kill cells immediately after synthesis [48]; a delay of
several hours for a colicin to be exported following a period of induction
has been reported [23,49]. Colicin E2 has been found in both the cyto-
plasm and periplasm following induction [50] whereas colicin A and
cloacin DF13 were found principally in the cytoplasm [44,51]. A one
step model for colicin export was proposed in which colicin is released
directly into the extracellular environment through imperfections in the
lipid bilayer at points of close association between the IM and OM and
thus bypassing the periplasm [44]. However, colicin Awas subsequently
shown to accumulate in the periplasm at various time points following
induction with mitomycin C suggesting a two-step model of release
after the Cal-mediated translocation across the IM [45]. No BRP has
been reported for colicin B [18,52] and the mechanism of release of
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[53].3. Crossing the outer membrane
Colicin import is a unique event in the transport of proteins across
membranes interfaces. The colicin is faced with a number of obstacles
in its navigation across the OM, through the periplasmic space and pep-
tidoglycan layer and, in the example of the enzymatic colicins, across
the IM. The ﬁrst step in colicin transport of all colicins, except colicin
N, is the recognition by the R domain of a high afﬁnity outer-
membrane protein receptor on the E. coli cell surface such as BtuB, Cir,
FepA, FhuA, Tsx or porins OmpA and OmpW (see Table 1). In contrast,
the R domain of ColN targets the sugarmoieties of LPS as its initial bind-
ing step [54] in a process that is more analogous to type RF pyocins and
lectin-like bacteriocins from Pseudomonas spp. than other group A coli-
cins [55–57]. High afﬁnity outer membrane receptors are 22-stranded
β-barrels that contain an N-terminal globular domain that inserts into
the cavity of the barrel and acts as an internal plug. The plug domain
contains a short stretch of ~5 residues at the N-terminus called the
TonB box because it interacts with the C-terminus of TonB at the peri-
plasmic side of the OM [58]. It has been suggested that movement of
the plug domain into and out of the β-barrel facilitates the uptake of
small metabolites and ion-chelators through the channel of the barrel
[59].
Colicins also have similar short consensus sequences in their N-
terminal translocation domains termed a TonBbox (for TonBdependent
colicins) or TolB box (for Tol-dependent colicins; colicins N and E1 are
exceptions as they are TolB independent and do not have a TolB box;
Table 1). Based on the positions of the TonB boxes in the crystal struc-
tures of ColIa and ColB, it was suggested that colicins also penetrate
the outer membrane through the cavity of the barrel in an unfolded
state following competitive displacement of the plug from its interac-
tion with TonB [60,61]. Later studies investigating the effect of ColB on
the exposure of cysteine residues engineered into the FepAplug domain
to externally added ﬂuorophores either supported [59] or challenged
[62] the validity of this classical model of colicin translocation [63]. Sim-
ilar studies using cysteinemutations of residues in constricting loops of
the channels of the OmpF porins on the activity of colicins A andN dem-
onstrated that neither colicins A nor N crossed the OM through the
lumen of the OmpF pore [64,65]. Instead, colicin N feeds down the
side of OmpF following displacement of tightly bound lipid on the exte-
rior of its translocator [66]. The recently discovered phenomenon that
ColN binds to LPS as its primary receptor and uses OmpF as a
translocator has prompted an alternative model of ColN import [46].
Since the LPS is further from the surface of the membrane than OMPs,
binding of the R domain to LPS sugars positions the IUTD above the ex-
terior of ompF and may promote threading of the IUTD through the
lumenof an adjacentOmpF barrel using theOBS as a pullingmechanism
once inside the pore [46]. Recent studies by Jakes and Finklestein [11]
have demonstrated that two copies of Cir are required for the activity
of ColIa; one as the primary high afﬁnity receptor and the second copy
as a translocator for insertion of the ColIa IUTD [11]. By swapping the
R domain of ColIa with that from ColE3 which binds BtuB as its primary
OM receptor they created a chimeric colicin called IaE3R that became
dependent on the E3 receptor, BtuB for its killing activity. However,
cells devoid of Cir were equally resistant to IaE3R as well as ColIa sug-
gesting that Cir might also be responsible for translocation processes
of colicin import after receptor binding. Interestingly, both the wild
type ColIa, IaE3R and even a deletion mutant of ColIa with no R domain
still retained marginal cell killing activity against a BtuB mutant while
the isolated pore-forming C-domain on its own showed no in vivo tox-
icity suggesting that the ColIa T domain may indeed bind to Cir in the
absence of the R domain to initiate cell killing [11]. The isolated IUTD
of ColN has recently been found to confer residual activity againstE. coli by a mechanism that remains dependent on OmpF and TolA but
independent of membrane insertion [67].
The crystal structure of colicins in complexwith their primary recep-
tors [68–70] have been instrumental in proposing novel models of coli-
cin uptake across the OM [71,72]. Alternative mechanisms for colicin
translocation across the OM have been proposed that involves the for-
mation of a colicin translocon [10,73–75].
3.1. Formation of a colicin translocon
Despite high afﬁnity binding (kD b 10−9 M) between the long
coiled-coiled R domains of ColE3 or ColE2 and the primary receptor
BtuB, the central plug containing the TonB box of BtuB did notmove sig-
niﬁcantly to expose the pore wide enough for the colicin to enter
through nor was there a signiﬁcant change in conformation of the coli-
cin or BtuB to reconcile transport of the colicin through theBtuB channel
[68,69]. Moreover, the R domain was found to be angled at 45° with re-
spect to the OM surfacewhich positioned the other two domains (C and
T domains) further away from the primary receptor and towards other
more abundantOmps (Fig. 2) [68,69]. The extended length and trajecto-
ry of the R domain of ColE2 and ColE3 acts as a ‘ﬁshing pole’ for the T do-
main to locate its translocator, OmpF in this case, for transport across
the OM (Fig. 1). OmpF is one of the most abundant proteins in the OM
and exists as a trimer of identical 16 stranded β-barrels [76]. It is essen-
tial for the translocation of TolQR-dependent E colicins and colicins A
andN [77,78]. Occlusion of the OmpF channels in planar lipid bilayer ex-
periments by the T domain of ColE3 implied that the T domain may in-
sert into the porin, whichwas later conﬁrmed by the crystal structure of
the IUTD of ColE3 in complexwith OmpF [79]. Evidence for formation of
a colicin translocon came from the extraction of an intact complex at the
cell surface of BtuB-ColE9-Im9-OmpF that was dependent on the pres-
ence of the 83 residues of the intrinsically unstructured T domain
(IUTD) for quaternary complex formation [75]. Deletion mutagenesis
of the IUTD of ColE9 and interactions of the mutants with OmpF re-
vealed two non-contiguous regions, or OmpF binding sites (OBS1 and
OBS2) of the ColE9 IUTD that interacted with OmpF with binding afﬁn-
ities of 2 μM and 24 μM, respectively [71]. Site-directed mutagenesis of
individual residues across OBS1 did not abolish the interaction of the
IUTD peptidewith OmpF but demonstrated the importance of ﬂexibility
of the whole molecule to threading of the peptide through the lumen of
OmpF [80]. Although neither OBS is essential for the cytotoxicity of the
enzymatic colicin, the presence of two OBS domains make killing more
efﬁcient by acting sequentially to deliver the TolB box (sandwiched be-
tween both OBS regions) through the OM and to its binding site on TolB
in the periplasm. Recent data by Colin Kleanthous and colleagues has
advanced our understanding of the colicin translocon model showing
that TolB is tethered to the colicin translocon via both OmpF binding
sites, which occupy two of the three subunits of OmpF in an antiparallel
conﬁguration as OBS1 is able to insert into OmpF in either orientation
(Fig. 3; [10]). It remains to be seen whether a similar model of
translocator threading occurs for other Tol-dependent colicins such as
ColA which have different biological activities or structural
characteristics.
3.2. Immunity release
All E. coli cells producing colicins protect themselves by co-
synthesizing a plasmid-encoded immunity protein (Im) that prevents
the host cells committing suicide prior to colicin secretion. This is im-
perative for enzymatic colicins as the nuclease domains are active on
synthesis andwould degrade cellular DNA/RNAwithout the neutraliza-
tion by constitutively expressed immunity protein [28]. Enzymatic im-
munity proteins protect host cells against cognate colicins with
binding afﬁnities in the femtomolar range but are unable to offer protec-
tion against non-cognate colicins at physiological levels despite show-
ing micromolar binding afﬁnities in vitro [81,82]. Indeed, dual
Fig. 2. Crystal structures of colicins in complex with their primary receptor. Complexes of the R domains of ColIa with Cir (pdb, 2HDI) [93] and ColE3 with BtuB (pdb, 1UJW) [95] dem-
onstrating binding of the colicin R domain to the receptor at an oblique binding angle of ~45° to point the colicin away from the primary receptor and towards other Omps during the
formation of a translocon.
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on the same colicinogenic plasmids expressing enzymatic colicins pre-
sumably to offer protection against attack by the cognate nuclease
[83]. For producers of pore-forming colicins such as ColA that exhibit
single hit kinetics (one colicin molecule kills one cell), the immunity
protein forms part of the integral IM proteins that either prevent orFig. 3.Model of the colicin translocon. ColE9-Im9 complex binds to its high-afﬁnity primary re
binding sites (OBS1 and OBS2) within the IUTD of ColE9 occupy two of the three subunits of O
in a ﬁxed orientation. Allosteric signalling of TolB forces immunity release at the cell surface.block the depolarizing channel formation by the invading colicin pore-
forming domain at the cytoplasmic membrane [84]. ColM differs from
other colicins because it kills cells by inhibiting peptidoglycan biosyn-
thesis [85]. The ColM immunity gene, cmi is found adjacent to the
ColM activity gene, cma on the pColBMplasmid but both genes are tran-
scribed in opposite directions and ColM does not form a complex withceptor BtuB recruiting the translocator protein OmpF via its IUTD (red dots). Both OmpF
mpF in an antiparallel conﬁguration to tether TolB in periplasm to the colicin translocon
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munity protein of ColM is anchored to the outer leaﬂet of the IM by an
N-terminal hydrophobic α-helix that positions a globular α/β folded
C-terminal domain into the periplasm to inactivate the imported ColM
at the membrane interface by an unknown mechanism [86,87].
Nuclease immunity proteins are approximately 10 kDa and released
from cells as a heterodimer of ~70 kDawith the colicin [88,89]. They inac-
tivate enzymatic colicins either by binding directly to the nuclease active
site and mimic their substrate RNA (Eg. tRNase-speciﬁc immunity pro-
teins, Im5 and ImD) [90,91] or by binding at an exosite away frombut ad-
jacent to the active site that blocks access to their substrates, DNAor rRNA
(e.g., DNase colicins E2, E7, E9 or rRNase colicins E3, E4, E6 [92–94]).
Enzymatic colicins bind to outer membrane receptors as an inactive
complex with their cognate immunity proteins. At some point after
binding, immunity is jettisoned from the colicin complex and the nucle-
ase is transported to the cytoplasm to kill the receptive cell. Studieswith
recombinant colicin/Im complexes and/or uncomplexed colicin have
shown that DNase colicins retain full activity in the absence of any com-
plexed immunitywhereas the activity of RNase colicins such as ColE3 or
CloacinDF13 is dependent on the presence of complexed immunity that
is then lost after receptor binding [95–98]. The crystal structure of the
ColE3-Im3 complex revealed that in addition to its interaction with
the C domain (RNase), up to 38% of the Im3 protein also interacts with
T domain [99,100] and that the bipartite binding of immunity to both
domains in RNase colicins stabilizes the colicin in a favourable conﬁrma-
tion for biological activity prior to colicin import [95].
It is believed that the immunity protein is released from its heterodi-
mer at the cell surface shortly after binding to its high afﬁnity outer
membrane receptor [95] but prior to the transport of the nuclease do-
main across the outer membrane [71,101]. Immunity protein of cloacin
DF13 was found in culture supernatants of E. coli cells 10–20 mins after
treatment with cloacin DF13 [95] and alexaﬂuor labelled Im9 has been
detected in culture supernatants of cells following reduction and re-
sumption of activity at the cell surface of an inactive disulphide locked
ColE9 [101]. Recent evidence has suggested that ColE3-Im3 complex
dissociation requires the translocation of the IUTD of ColE3 through
OmpF which weakens the interactions of Im3 with the T domain en-
couraging the release of Im3 at the cell surface [96,102,103]. However,
the T domain of ColE9 is known to have limited interactions with
wild-type ColE9 or the isolated DNase domain suggesting that the
sandwiching of immunity proteins between the C and T domains may
not be a general feature of all nuclease colicins [81]. It was demonstrated
that receptor binding and recruitment of OmpF by the T domain of
ColE9 during the formation of the BtuB-OmpF-ColE9 translocon was
not sufﬁcient to release Im9 from the ColE9-Im9 complex [75] but that
unfolding must occur after binding to BtuB and prior to immunity re-
lease [75,101]. Furthermore, Duché et al. [104] have shown that release
of Im2 from the ColE2-Im2 complex required an outer membrane
translocon including BtuB, OmpF or OmpC as well as functional TolA
and TolB proteins, and the interaction of a TolA binding region of TolB
(termed the TolA box) with TolAIII was necessary for Im9 release from
ColE9-Im9 and import of the ColE9 DNase domain [105]. In addition to
a functional import machinery, the energy supply dissipated by the IM
PMF via the Tol system was also found to be essential for Im9 release
from the ColE9-Im9 complex [106].
The crystal structures of the complexes of the BtuB receptor and the
R domains of colicins E2 and E3 not only provided evidence for the for-
mation of the translocon with OmpF and Tol (detailed in Section 3.1)
but implicated the importance of ﬂexibility and unfolding of the extend-
ed helical arms of the R domain for immunity release and entry of the
nuclease domains across the OM [68,69]. Rigidity engineered across
both helical arms of the R domain by the insertion of an inactivating di-
sulﬁde bond at the neck of the R domain prevented activity that was
only reversed by DTT treatment [107], and global conformational rear-
rangement across all three domains of ColE9 at the cell surface has re-
cently been demonstrated for ColE9 activity and Im9 release [108].One of the biggest conundrums associated with immunity release
over the previous 20 years has been the discrepancy that exists be-
tween the high binding afﬁnities associated with the slow dissociation
rate constants for the colicin-immunity interaction and the energy
source needed to accomplish rapid dissociation of immunity from coli-
cin at the cell surface [109]. The minimum amount of energy required
for removal of immunity protein with a Kd = ~10−14 was estimated
to be between−20 Kcal mol−1 and−24 Kcal mol−1 [72] whereas all
known energy transducing systems available such as the PMF are
thought to be able to supply up to 3.5 Kcal mol−1 which assumes a
huge shortfall in the energy requirements needed [13]. However, recent
work by Farrance et al. [12] using atomic forcemicroscopy and disulﬁde
bonds engineered into the DNase domain have shown that Im9 is re-
leased from the colE9-Im9 complex following a conformational rear-
rangement of the DNAse domain in response to low forces (b20 pN)
triggered by a conformational remodelling of the T Domain on binding
TolB. This results in an enormous increase (106-fold) in the dissociation
rate of the ColE9-Im9 complex and reduces the lifespan of the complex
fromdays tomilliseconds commensuratewith the speed of intoxication,
supporting a role for the establishment of the outer membrane
translocon and PMF in immunity protein release [75,101,106].
4. Translocation
4.1. Tol-dependent translocation
Conservation of the sequence of genes of the tol–pal operon across a
variety of bacterial orders suggests important functional signiﬁcance of
the Tol proteins [110]. Though their normal cellular function in E. coli is
still uncertain [110], the Tol–Pal complex appears to play a role inmain-
taining the integrity of the cell envelope, transducing energy from the
cytoplasmic membrane, and may form a dynamic sub-complex at con-
striction sites to promote the energy dependent septal wall formation
across invaginating peptidoglycan and inner membrane layers during
cell division [111–114]. In addition, the Tol-Pal complex has become a
surrogate platform for entry of external agents such as bacteriocins
and ﬁlamentous bacteriophage. The Tol–Pal system consists of ﬁve pro-
teins, TolA, TolB, TolR, TolQ and Pal. TolA is a 44 kDa periplasmic protein
organized into three domains which are separated by clusters of glycine
residues [115]. It is anchored to the cytoplasmic membrane via its N-
terminus [116], spans the periplasm via its extended central domain
(TolAII), and binds to both TolB [117,118] and Pal [119] via its C-
terminal domain (TolAIII). All group A colicins are dependent on TolA
which is integral to the Tol–Pal complex and has been likened to a pro-
miscuous hub protein that forms interactions with intrinsic and extrin-
sic proteins at several different interaction sites [120,121]. TolQ and
TolR are transmembrane proteins that are involved in the PMF-
dependent activation of TolA [111], which shuttles energy from the IM
to OM because of its association with Pal anchored to the outer mem-
brane [122,123]. TolB is a periplasmic protein, that is associated with
the outer membrane via an interaction of its C-terminal β-propeller do-
main with the peptidoglycan-associated lipoprotein (Pal) [124], and
with TolA via its N-terminal domain [117]. Apart from the translocation
of ColN, ColE1 and cloacin DF13, recruitment of TolB appears essential
for the import of Group A colicins (Table 1). Comparison of the three-
dimensional structures of TolB on its own [125,126] and in complex
with the T domains of ColA and ColE9 carrying linear TolB binding epi-
topes, named the TolB box, have revealed important functional differ-
ences between the enzymatic colicins and ColA for the common TolB
binding interface [127,128]. The afﬁnity of TolB for the TolB box of
ColE9 is approximately 10 fold higher than that of the TolB box of
ColA with TolB [129]. Consequently the TolB box of ColE9, but not of
ColA, is able to competitively recruit TolB from its physiological interac-
tion with Pal producing a conformational change in TolB that encour-
ages a low afﬁnity interaction of the N-terminus of TolB with TolAIII,
which is important for immunity protein release of the ColE9/Im9
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was established after favorable substitutions were engineered into the
ColA TolB box [127], it is clear that recruitment of TolB by ColA is differ-
ent to that of the enzymatic colicins. TolB binds to other outer mem-
brane receptors such as Lpp and OmpA [130,131] and maybe present
in the periplasm as a smaller protein that shuttles betweenmembranes
[132,133]. It is therefore possible that ColA interacts with TolB directly
in the periplasm or from a lower afﬁnity complex at the outer mem-
brane. The lower afﬁnity interaction of the TolB box of ColA with TolB,
as compared to that of ColE9, may be important for the subsequent
higher afﬁnity interaction of ColA with TolA [120,129,134], which is a
component of the Brownian ratcheting process that has been proposed
to drive the unidirectional translocation of groupA colicins [135]. ColA is
unique in colicin biology in possessing different binding sites for two Tol
proteins and as such resembles the infection of E. coli by ﬁlamentous
phages [136]. Filamentous phages infect E. coli in a two-step process
that involves the interaction of two N terminal domains of the g3p pro-
tein of phage fd (D2 andD1) that bind to cell pili and TolAIII respectively
in a sequential manner [137]. The g3p interaction site with TolAIII con-
tains a tetrapeptide motif (CYGT) that is also conserved in the TolA
binding domains of colicins A, K and N [14]. There is currently no pub-
lished evidence to suggest that the TolA binding region (extending
from residues 52-97) and TolB box domains of ColA interact with each
other in a similar way to the D1 and D2 domains of g3p. Comparison
of the crystal structures of TolA in complex with bacteriophage fd g3p
protein and the TolA binding domain of ColA [135,138] shows both
complexes have opposing binding interfaces [120,136]. Nevertheless,
the establishment of a trimeric complex of TolA:TolB:ColA in vitro sug-
gests that ColA might interact with TolA and TolB simultaneously fol-
lowing a two-step process [139].
TolA is also required for the entry of Colicins N and E1 [140,141].
NMR experiments have revealed that the IUTD of ColN binds to TolAIII
in an interaction that is strikingly similar to the g3p–TolAIII complex
[136,142,143]. The lack of any sequence or structural homology be-
tween the TolAIII binding sites of ColN and g3p implies that they have
evolved by convergent evolution to fulﬁl the same biological task
[143]. Colicin E1 interacts with TolA differently than other group A coli-
cins; deletion of domain II of TolA,whilst being catastrophic to the activ-
ity of other groups A colicins, only has a slight effect on ColE1 activity
that reﬂects its unusual dependence on TolC for transport through the
OM [144]. ColA is also dependent on TolC for biological activity [145]
but a role for TolC in the import of ColA, unlike that of ColE1, has not
been established (Table 1). TolC is present in the cell envelope at adhe-
sion zones [146] and may therefore provide a direct route for ColE1 to
the TolQRA complex through constrictions of the cell membranes.
Despite the identiﬁcation of a putative TolR box in theN-terminus of
colicin E3 a direct interaction of TolQ or TolR with any colicin has not
been demonstrated [147]. The IM transmembrane regions of TolQRA
stabilize TolA in a suitable conﬁrmation for dissipation of the IM PMF
that ensures the maintenance of OM stability [116]. TolR interacts
with TolA by interactions with its N-terminal transmembrane domain
and surface exposed C-terminal domain and with TolQ through an in-
teraction of its C-terminal domain which becomes associated with the
IM by its interaction with TolQ [148,149]. TolQ has three transmem-
brane helical domains and interacts with TolA through an interaction
with the ﬁrst helix and with TolR by an interaction with its second
and third helices [149,150]. Disruption of IM interactions by site direct-
ed mutations to discriminative residues of TolQR that reside in a puta-
tive aqueous ion channel resulted in destabilization of the OM but did
not affect colicin activity [112].
4.2. Ton-dependent translocation
The Ton system consists of an OM receptor and three proteins an-
chored in the IM; TonB, ExbB and ExbD that share functional and struc-
tural similarities to the Tol system proteins TolA, TolQ and TolRrespectively [151,152]. The Ton system has been parasitized by Group
B colicins and bacteriophages T1 and phi80 for import into sensitive
cells [153]. ExbB and ExbD are analogous to TolQ and TolR respectively,
and harvest the energy from the IM PMF to energize TonB [154]. Muta-
tional and cross-linking studies show that partners may be interacting
as oligomers [157] with the ratios of TonB:ExbB:ExbD per cell equiva-
lent to 1:7:2 respectively [158]. ExbB is thought to be a primary scaffold-
ing protein since both TonB and ExbD are unstable in its absence [155],
and is an integral component of the energy coupling system for the
transport of vitamin B12 [156]. ExbD interacts with TonB in the peri-
plasm and has a role in regulating the energy-dependent conformation
of TonB for speciﬁc interactions with transporters [159,160].
Cross complementation between the Tol and TonB systems has been
demonstrated such that TolQ and TolR can replace ExbB and ExbD re-
spectively, albeit at low levels (10–20%) for TonB-dependent transloca-
tion of colicins [151,152] and the Ton system can functionally replace
TolB in the uptake of colicin U by converting the ColU TolB box to a
TonB box of its T domain [161]. Braun showed that colicins B and D,
two group B colicins are still active on ExbBD mutants. Activities of
group B colicins and cobalamin transport were completely abolished
in a TolQR-ExbBD mutant [156,152] while the over expression of TolQ
and TolR in an ExbBDmutant background rendered cells more sensitive
to those two colicins [152]. In contrast, no cross-complementation be-
tween TolA and TonB has been observed [152] despite a common evo-
lutionary relationship between their C terminal domains [162].
TonB is a ~26 kDa protein that is mechanistically analogous to TolA
[163]. It is divided up into three domains: Domain I contains the
amino terminus from residues 1–65 that has a standard hydrophobic
signal sequence necessary for the Sec-dependent export of TonB to the
IM. TonB is exported without proteolytic cleavage which serves to an-
chor TonB to the IM allowing the predominantly hydrophilic domain II
(residues 66–102) to extend into the periplasm. Domain II is unusually
rich in proline residues which are not necessary for energy dissipation
to the OM but encourage a conformational plasticity that extends the
protein across the periplasm towards the inner leaﬂet of the OM
[164]. The third domain consists of residues 103–239 and has a hydro-
phobic region at its C‐terminus that may localise TonB to the OM. The
C terminal domain interacts with the TonB box of the OM receptors
such as BtuB, FepA and FhuA [165,166] to facilitate energy transduction
across both membranes for TonB-dependent coupling of IM and OM
processes. Group B colicins have a sequence of 5 residues in the N‐ter-
minus that has been termed the TonB Box from its conservation with
the TonB box of the plug domain of OM receptors [77]. Mutations to
the TonB box of colicins B and M produced mutants that were inactive
due to a perturbation in translocation of the colicin that were partially
suppressed by mutations in TonB, suggesting that uptake is TonB de-
pendent [167,168]. It was originally envisaged that colicins use the
TonB box to interact with TonB following displacement of the TonB
box of the plug of the OM receptor [85,86]. However, the crystal struc-
ture of colicin Ia bound to its OM receptor, Cir showed that the tip of
the R domain of ColIa penetrated the outer surfaces of the ligand-
binding pocket of Cir to expose but not dislodge the plug from its central
position [95]. Nevertheless, individual missense mutations to residues
Arginine 158 and Proline 161 of TonB, which lie at the binding interface
of the TonB:TonB box of the FhuA and BtuB plug domains [83,169], ren-
dered cells resistant to ColD but sensitive to Colicins B, M, Ia and bacte-
riophage phi80 [170]. Sensitivity to ColD was restored in suppressor
mutations of the TonB box of ColD [170]. Given that the TonB box of
ColB can functionally replace the equivalent pentapeptide of ColDwith-
out affecting the activity of ColD, it is likely that translocation of colicins
B and D is functionally dissimilar despite sharing 96% identity across the
T and R domains [170]. Interestingly, microcins require TonB for cellular
import but do not possess an apparent TonB box [171] and given their
small size probably enter the cell in a process that is similar to the up-
take of iron siderophore complexes [172] or antibiotics that bind the
OM plug independently of the TonB: TonB box interaction [173].
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the cell but the precise mechanism of uptake is currently unclear [174,
175]. Meanwhile, colicins 5 and 10 have a TonB box in their T domain
and are Ton dependent but independent of the Ton system with regard
to the OM receptor, Tsx [176] (Table 1).
The recent discovery that colicin Ia uses a second copy of Cir as a
translocator raises the question of whether two copies of TonB are
necessary for translocation of the ColIa pore-forming domain. The
current model of ColIa import assumes that the formation of the ColIa-
Cir(R-domain)-Cir (translocator) complex mimics binding of its natural
ligand to the receptor which facilitates binding of the TonB box of Cir to
the C-terminal domain of TonB following an order–disorder transition
of the Cir TonB box [177]. The Cir plug becomes distorted or displaced
out of the barrel to allow movement of the IUTD through the pore into
the periplasm and promote binding of the TonB box of ColIa to either
a second copy of TonB or the same copy of TonB following displacement
from its interactionwith the TonB box of Cir (Fig. 1) [11]. TonB is able to
dimerize in vivo [178] and forms a 2:1 (TonB:FhuA) stoichiometry with
FhuA [179] that is dependent on the presence of the TonB box [180] but
recent evidence using double electron–electron resonance has shown
that when bound to either FhuA, FepA or BtuB, the TonB dimer is con-
verted back to its monomeric form [181].5. Crossing the inner membrane
5.1. Integrations with the cytoplasmic membrane
Colicin DNases and rRNases are characterized by sequences rich in
basic residues within their C-domains despite being structurally very dif-
ferent, suggesting that their import across the IM is electrostatically driv-
en and may be structurally independent [93,182]. Studies looking at the
interactions in vitro, between the membrane and the nuclease domains
of ColE9 and ColE3 showed signiﬁcant structural destabilization as result
of their interaction with anionic phospholipids [183,184]. Colicin DNases
such as ColE9 are able to form short lived, non-voltage gated channels
with planar lipid bilayer in contrast to pore forming colicins that do not
cross the IMbut are inserted into the IM to formvoltage dependent chan-
nels upon helix reorganization with longer half-lives and with the ability
to cause IM depolarization [185]. This DNAse-induced channel activity
was prevented by an internal disulﬁde bond within the nuclease domain
that also abolished Col toxicity and implied that structural ﬂexibility in-
dicative of destabilization of the nuclease domain was essential for inter-
actions with the IM [185]. In other studies, it was shown that there is a
direct correlation between the net positive charge on the DNase and
the cell killing efﬁciency such that colE7 N colE2 N colE8 N colE9 implying
that DNase colicinswith a higher net positive charge havemore desirable
pharmacokinetic properties [186]. However, a correlation between net
positive nuclease charge and association kinetics of the nuclease with ar-
tiﬁcial large unilamellar vesicles (LUVs) in vivo was not substantiated,
suggesting that in the presence of sufﬁcient negative charge at themem-
brane surface, membrane afﬁnities of nuclease domains are not affected
by increases in net positive charge of the nuclease [187]. Nuclease do-
mains bind anionic membranes only with micro-molar afﬁnity and via
a co-operative bindingmechanism such that the initial non-speciﬁc elec-
trostaticmembrane associationwith basic nuclease domainsmay allow a
conformational rearrangement to facilitate further speciﬁc hydrophobic
interactions that drive insertion depth and destabilization at the mem-
brane interface [187]. Interestingly, for all colicins tested, insertion
depth correlatedwellwith increased lipidmixing and vesicle aggregation
and was a reﬂection of relative hydrophobicity such that the greatest
insertion depth was observed for ColE3 followed by the DNases E7 N E9
N E8 [187,188]. Colicin E3 inserts into the top region of the hydrophobic
core and the DNases traverse the interfacial region of the bilayer suggest-
ing a direct correlation between individual cleavage mechanisms and
depth of lipid bilayer insertion (Fig. 4).Evidence for a role of the IM-associated translocator, FtsH in the
import of nuclease domains through the IM by a process of retro-
translocation analogous to that used by bacterial toxins to move
unabated through the lipid membranes of eukaryotic cells has been
established [186]. FtsH is an essential ATP dependent protease in the
E. coli that spans the IM with two transmembrane regions and extends
into the cytoplasm through a large cytosolic domain that contains the
protease activity [189,190]. It functions to dislocate mis-folded mem-
brane proteins from the IM to the cytoplasm and then degrades them
[191]. Retro-translocation of colicins across the IM is one of the least
known processes in colicin import. IM-associated destabilization of
colicin nuclease domains may provide a conduit to FtsH directly or alter-
nativelymembrane embedded chaperone proteins such as HﬂC andHﬂK
may facilitate access to FtsH through their interactionwith FtsH as a large
multimeric complex of proteins [192] (Fig. 3). FtsH is required for the
biological activity of both group A and group B nuclease colicins
(DNase, tRNAse or rRNase) and has been implicated in the IM transloca-
tion of ColD but not ColE3 through its interaction with LepB [193] but is
not required for the cytotoxicity of pore-forming colicins of either trans-
location dependent system [186]. How the unfolded colicin evades FtsH
mediated degradation at the interface between IM and cytoplasm is
unknown but itmaybe a combination of the rapid re-folding characteris-
tics of colicin nuclease domains in an aqueous environment and/or
the inability of FtsH to degrade sequestered proteins that contain
periplasmically exposed domains with tightly folded regions [194].
5.2. Proteolytic processing
In the third and ﬁnal step of translocation, pore-forming colicins
generate a pore in the inner membrane causing a localized depolariza-
tion whilst nuclease colicins require further translocation through the
inner-membrane (IM) and into the cytoplasm to access their target
material such as DNA or RNA. As most research on colicin transport
over the last decade has focused on OM translocation, progress on an
understanding of translocation through the inner membrane remains
relatively sketchy. Recent studies have revealed that IM translocation
of enzymatic colicins is likely to involve some proteolytic processing
of the colicinwith somedegree of interaction between the cytotoxic do-
main of colicin and the IM, retro-translocation that involves a localized
destabilization of the nuclease domain and refolding into holoprotein
once reaching the cytoplasm [183,187]. The role of endo-proteolytic
cleavage of the active cytotoxic domain into the cytoplasm remains a
topic of conjecture. It has been reported through studies on colicins E2
and E3 that the colicin remains in tight binding with their primary OM
receptor and import machinery during the IM translocation of nuclease
domains into the cytoplasm suggesting that cleavage of the colicin
shortly after receptor binding or transport through the OM to release
the cytotoxic domain at an early stage of translocation does not occur
[195]. However, many studies have suggested that proteolytic cleavage
of colicin nuclease domains does occur, but its link to the import
mechanism is often less clear. Bacterial OM protease OmpT has been
an attractive candidate for proteolytic cleavage of colicins at the cell
surface; colicins E1-E3 andAwere shown to be cleaved byOmpT releas-
ing a fragment containing cytotoxic domain [196,197]. ColE7 also un-
dergoes cleavage at the residue arginine 447 of the colicin molecule in
an OmpT dependent manner [198] but the gene product responsible
for such a proteolytic event could not be identiﬁed from a genome-
wide screen of the Keio collection [145], and the corresponding
residue in the DNase domain of ColE9 was shown to be an essential res-
idue for DNAse activity of colicin E9 [199]. In addition, the BtuB bound
ColE2-Im2 complex protected OmpT proteolytic processing of ColE2 at
the cell surface [196]. However, the involvement of OmpT for the import
and toxicity of nuclease colicins has recently been refuted as an OmpT
deletion mutant of E. coli retained full-sensitivity to the ColD and
ColE3 RNases [193], and it has been suggested that OmpT plays a part
of the general bacterial defence system against exogenous toxins such
Fig. 4. Transport of the nuclease domain through the IM. The nuclease domain of colicins is selectively transported from the periplasm to cytoplasm across the innermembrane through an
interaction with FtsH. 1. The nuclease domain interacts with the inner membrane. 2. Nuclease unfolding occurs within the membrane. RNase colicins such as ColE3 penetrate into the
hydrophobic core whereas DNAse colicins enter the IM at the interfacial region of the lipid bilayer. 3. Following interaction with a complex of FtsH, Hﬂk and HﬂC, the nuclease is re-
folded into its active form in the cytoplasm.
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leader protease LepBwas implicated in the processing of ColD to release
the RNase fragment [202,203]. LepB interacts with ColD in vitro, and
mutated forms of LepB carrying the mutations Arg274Lys and
Lys145Ala as individual substitutions prevented binding and catalysis
of ColD, respectively [202,204]. The same group recently showed that
LepB in isolation failed to cleave ColD implying that it is necessary, but
not sufﬁcient, for endoproteolytic processing of ColD on its own [193].
Moreover, LepB protein was not found to be necessary for cytotoxicity
of other colicins (ColB and ColE1-E3) indicating that this is a very specif-
ic effect for ColD.6. Import of colicin-like bacteriocins from
other Gammaproteobacteria
Bacteriocins with similarities in their genetic organization and
domain structure to colicins have been identiﬁed in several other
γ-proteobacteria such as pyocins from Pseudomonas aeruginosa,
pesticins from Yersinia pestis, klebicins (Klebocins) from Klebsiella
pneumoniae, cloacins from Enterobacter cloacae, lumicins from
Photorhabdus luminescens and several colicin-like bacteriocins active
against plant pathogenic bacteria from Ps. syringae and Pectobacterium
spp. Partial DNA sequence homologies with colicin domains, X-ray
structure determination and site-directed mutagenesis studies have
advanced our understanding of the mechanisms by which these
colicin–like bacteriocins are able to bind cells and to kill them but
very few studies have provided compelling evidence for any speciﬁc
import processes across the cell envelope. In the absence of any direct
binding studies that show an interaction of the T domain of a colicin-
like bacteriocin with a host cell protein or other macromolecule, for
example, TolA/B or TonB, most evidence for any import mechanisms
of colicin-like bacteriocins relies on indirect comparisons of the
translocation processes adopted by colicins.6.1. Pyocins
Pyocins are chromosomally encoded bacteriocins classiﬁed into three
different types (Type R, F and S) which are structurally and functionally
distinct. They are produced by more than 90% of all Pseudomonas
aeruginosa strains with any one strain being capable of producing more
than one pyocin type [205].
Pyocin production is induced by DNA damaging agents such as ultra-
violet (UV) irradiation and mitomycin C via the RecA dependent path-
way. Mutagenic agents trigger the expression of RecA which causes the
cleavage and release of the pyocin repressor, PrtR from the promoter of
prtN allowing synthesis of PrtN and subsequent expression of the pyocin
genes. They are usually produced against related strains but activity has
been reported against other distantly related Gram negative organisms
[206].
Themajority of studies on pyocin import so far have concentrated on
the identity of the primary cell surface receptors used by pyocins for
receptor binding. The ferripyoverdine or ferripyochelin receptors
normally involved in the import of iron-siderophore complexes are in-
volved in the uptake of soluble pyocins via the N-terminal R domain
whereas the lipopolysaccharides (LPS) are implicated in the entry of
the phage-like RF type pyocins via interactions of the tail ﬁbre region
of RF type pyocins with sugar residues of the outer core of LPS [56,
207–210]. The newly discovered pyocin L1 from P. aeruginosa has simi-
larity to the lectin-like family of bacteriocins from Pseudomonas spp. and
binds the monosaccharide D-rhamnose of the common polysaccharide
antigen (CPA) of P. aeruginosa LPS [55].
Very little is known about the mechanism of cell entry following re-
ceptor binding, translocation to the active site and the cascade of events
that culminate in the death of the non-immune cell. Based on similari-
ties of the domain organization of soluble pyocins to the colicins, it is
likely that the translocation of the soluble pyocins occurs through pro-
tein–protein interactions of the translocation domain with either the
Tol-dependent or the TonB-dependent translocation systems. The Tol-
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translocation of soluble pyocin AP41 following restoration of activity
of pyocin AP41 to a tol-like mutation in P. aeruginosa strain PAO1652
by complementation with tolQRA [211]. The crystal structure of TolAIII
of P. aeruginosa is similar to that of E. coli either alone [120] or in com-
plex with bacteriophage g3p [136] despite there being only marginal
homology of about 20% in the participating residues [162]. This might
imply that the recruitment of TolAIII by the translocation domain of
the soluble pyocins, for example pyocin AP41 from Pseudomonas
aeruginosa is actually very similar to that of TolAIII from E. coli by
group A colicins or phage g3p protein despite the interactions occurring
across a different binding interface [120,136,139]. However, the role of
TolA in the infection process of pyocins has not been conclusively deter-
mined because mutations of TolA, as controls for cell killing, have
proved problematic [211].
The role of TonB in the uptake of soluble pyocins has also been in-
ferred as TonB has a close associationwith the ferripyoverdine receptor,
FpvA and participates in pyoverdine mediated signalling [212]. The
crystal structure of FpvA is a transmembrane 22-stranded β-barrel,
with an extended N-terminal TonB box that forms intermolecular inter-
actions with TonB, and shares structural similarity to BtuB [213]. In ad-
dition, it has been suggested that uptake of the S type pyocins, S1, S2 and
S3 occurs via the TonB-dependent uptake system because these pyocins
show increased activity under iron limiting conditions and bind to a
ferripyoverdine receptor despite the absence of an obvious TonB box
in their translocation domains [214].
6.2. Pesticin
Pesticin is produced by Yersinia pestis to kill non-immune Y. pestis
strains, other Yersinia spp. and Escherichia coli strains that express the
primary receptor, FyuA used by pesticin to bind to sensitive cells
[215]. The pesticin structural gene, pst is synthesized in the opposite po-
larity to an adjacent immunity gene, pim on a small ~10 kb plasmid that
does not possess a lysis gene for lysis mediated pesticin release [216].
The crystal structure of pesticin has revealed a domain organiza-
tion that is very similar to the three domain organization of colicins:
an N-terminal translocation domain, a central receptor binding domain
and a C-terminal cytotoxic domain [217]. The ﬁrst 40 residues of the
N-terminus are intrinsically unstructured and are not visible in the
crystal structure; a characteristic similar to those colicins of which the
X-ray structure has also been determined. The cytotoxic domain has
structural homology to phage T4 lysozymes and kills cells by the hydro-
lysis of peptidoglycan similar to ColM although ColM interferes with
peptidoglycan synthesis rather than degradation of the murein layer
[218]. The pesticin OM receptor, FyuA has two domains: a β-barrel do-
main and an internal plug with a TonB box that is required for the up-
take of the iron siderophore, yersiniabactin [219]. Uptake of pesticin
occurs through the cavity of FyuA in an energy dependent process
that is driven by TonB, ExbB and ExbD [219]. Pesticin contains a TonB
box (DTMVV) at residues 3–7 of the N-terminal translocation domain
that likely interacts with TonB following displacement of the plug
of FyuA from its interaction with TonB [217]. Complete unfurling of
the IUTD appears critical for full activity of pesticin as any reduction in
the length of the imported IUTD has been predicted to signiﬁcantly
diminish its activity [217].
6.3. Colicin-like bacteriocins from phytopathogens (plant pathogenic
bacteria)
Recent advances in our understanding of the import processes and
biological activities of colicin-like bacteriocins from phytopathogens
justify their inclusion in this review. The majority of studies on colicin-
like bacteriocins active against plant pathogenic bacteria have been con-
ducted on carotovoricin, carocin, pectocin and syringicin. Carotovoricin
and carocin S1, S2 and D, are produced by Pectobacterium carotovorumsubsp. carotovorum (formerly Erwinia carotorova), which causes soft-
rot disease in plants. Carotovoricin Er is a high molecular weight bacte-
riocin with high sequence homology to bacteriophage proteins from
Salmonella typhi [220]. The genetic locus most closely resembles the
locus of RF-type pyocins and controls the expression of at least 10 pro-
teins that assemble into a phage structure with an antenna-like tail,
base plate and contractile sheath [220,221]. The mechanism of import is
currently unknown but presumably occurs by contraction of the sheath
and delivery of the core protein across the OM following adsorption of
carotovoricin to the cell surface. Carocins S1 and S2 are low molecular
weight bacteriocins with DNase and RNase activities respectively, and
are produced as a complex with their cognate immunity proteins similar
to the enzymatic colicins [222–224]. Carocin S1 gene has been shown to
have high homology to the pyocin S3 and pyocin AP41 genes of
P. aeruginosa, and gene expression is induced by the presence of energy
sources such glucose or lactose. The type III secretion system, integral to
the secretion of ﬂagella in P. carotovorum is involved in the extracellular
secretion of carocin S1 [223]. Unsurprisingly, domain III (cytotoxic do-
main) of carocin S2 has greater identity with RNase domains of colicin
D and klebicin D than with carocin S1 [224].
Carocin D has DNase activity and is produced as a complex with a
cognate immunity protein from adjacent genes, caroDK and caroDI, re-
spectively. Carocin D is a multi-domain protein with homology near
the N-terminus to the translocation domains of colicin E3 and cloacin
DF13 and at the C-terminus to both the translocation and cytotoxic do-
mains of S-type pyocins suggesting that the carocin D has two separate
translocation domains similar to colicin D and klebicin D [225]. An N-
terminal TonB box, DTMTV at residues 13–17 suggests that import of
carocin D across the periplasm is via the TonB-dependent translocation
system but a TonB-dependent high afﬁnity receptor or a receptor
binding domain has not, as yet, been elucidated [225].
Two novel bacteriocins, Pectocin M1 and M2, have recently
been identiﬁed from Pectobacterium spp. with sequence homology at
the C-terminus to colicin M and at the N-terminus to iron-sulfur con-
taining plant ferredoxins [226]. Competitive inhibition of the biological
activity of pectocinMby spinach ferredoxin I or by an inactivemutant of
pectocinMdefective in the catalytic domain showed that receptor bind-
ing of pectocin M and plant ferredoxin were mutually exclusive and
bind to an as yet unidentiﬁed common receptor [227]. In the absence
of a structure for pectocin M, it is probable that the ferredoxin domain
of pectocin provides the receptor binding function and another region
of the protein provides a mechanism for translocation through the cell
envelope to the cytotoxic site of action [227].
Syringacin 4A and M are other examples of colicin-like bacteriocins
produced by the plant-pathogenic bacterium, Pseudomonas syringae.
Syringacin 4A is induced by ultraviolet irradiation or mitomycin C
[228] and therefore is most likely regulated by the SOS response.
Syringacin M is a colicin M-like bacteriocin that kills susceptible cells
by disrupting peptidoglycan synthesis analogous to the mechanism of
peptidoglycan inhibition described for colicin M [7,229,230]. Despite
limited identity of the primary sequence of syringacinMwith the corre-
sponding sequence of colicin M, the recent crystal structure of
syringacinM showed striking structural similarities between syringacin
M and colicin M, not only of the expected cytotoxic C-domains but also
the receptor binding and translocation domains [231]. Weak electron
density at the N-terminus of syringacin indicated that the T domain is
unstructured and analogous to the IUTD of colicin M. Although an obvi-
ous TonB box has not been identiﬁed in the T domain of syringacin M,
the marked similarity with ColM suggests that import of syringacin M
across the cell envelope of P. syringae is TonB-dependent [231]. Indeed,
a mutant of syringacin M devoid of the likely TonB box-containing
region at the N-terminus is inactive. This unexpected evolutionary rela-
tionship between colicin M-like bacteriocins such as syringacin M and
colicins suggests the evolution of novel bacteriocins from a common
ancestor occurs through a process of diversifying selection rather than
a recombination event.
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Colicins offer excellent opportunities for a detailed understanding of
the processes that facilitate the import of bacteriocins and other protein
metabolites across the cell envelope of bacteria and/or membranes of
eukaryotic organelles. Over the last ten years, the determination of crys-
tal structures of colicins and the structures of colicins in complex with
binding ligands has resulted in rapid progress in our knowledge and
understanding of the mechanisms that control outer membrane pene-
tration of colicin domains through the formation of colicin translocons
at the cell surface. Similarly, the role of the Tol and Ton translocation
systems in the cell periplasm and the interactions of Tol and Ton with
intrinsic and extrinsic proteins have provided answers to questions on
uptake of colicins across the OM and the energy dependent release of
immunity protein from the nuclease domains of enzymatic colicins.
Indeed, the age-old paradox that existed between rapid immunity pro-
tein release at the cell surface and the perceived astronomical forces
needed to achieve this feat has now been resolved [12], and the exciting
new discovery that not all colicins bind high afﬁnity OM protein recep-
tors as the primary receptor binding step haswidened our knowledge of
colicin import processes [54]. In contrast, much less is known about the
transport of the cytotoxic domain through either the OM or IM, and the
mechanisms of proteolytic cleavage and transport of nuclease domains
across the IM which need further investigations.
With the impending demise of current antibiotic regimens against
manymulti-drug resistant bacteria especially against Gramnegative or-
ganisms producing extended spectrumβ-lactamases (ESBLs), the appli-
cation of bacteriocins as alternatives to antibiotics is gaining increased
popularity [232,233]. Nisin has been introduced as a preservative in
the food industry and as a prophylactic in veterinary healthcare.
Probiotics often produce bacteriocins that contribute to the establish-
ment of beneﬁcial bacterial communities in host micro-environments.
Several lanthipeptides are currently in clinical trials at different phases
for investigations as potential chemotherapeutic agents [232]. Colicins
have recently been shown to have good activity against pathogenic
E. coli existing within bioﬁlm communities [234,235], colicin M has
been suggested as a candidate for a novel antimicrobial agent because
its mode of action is common to all bacteria [236], and a hybrid phage
lysin based on the structure of pesticin has promising narrow spectrum
activity against members of the enterobactericeae [219]. However, the
clinical application of colicins is unlikely to depend on their mode of
action per se butmay focus on anunderstanding of the import processes
and ensuing interactions to disrupt essential cellular processes with
colicin domains or novel synthetic peptide mimics.
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